摘要
背景:利用可降解缓释生物材料包载利福平或异烟肼制成50μm以下的缓释降解肺靶向微球已多有报道,主要用于静脉注射肺靶向治疗研究。目的:研制长效缓释双组分药物人工骨,筛选最佳制备工艺并行体外释药特性观察。方法:采用乳剂-溶剂挥发法正交设计优化制备工艺,分别制备利福平聚乳酸-羟基乙醇共聚物微球和异烟肼聚乳酸-羟基乙醇共聚物微球。利用生物黏合剂将两种微球加工成长效缓释双组分药物人工骨。结果与结论:按照优化工艺分别制得聚乳酸-羟基乙醇共聚物载利福平26%、异烟肼28%的微球,并按质量各50%制成人工骨,体外释放90d保持0.02,0.03mg/L药物浓度。表明该人工骨有望为骨结核治疗用提供一种新型的方法。
BACKGROUND：Studies have shown that rifampicin or isoniazid covered with biodegradable sustained release materials can be used to prepare pulmonary targeting microspheres with less than 50 μm sustained-release degradation,which are mainly used for lung targeted therapy via the intravenous injection.OBJECTIVE：To develop long-term slow-release two-component drug artificial bone and to select the optimal preparation process of drug release as well as to observe the characteristics of in vitro releases.METHODS：Orthogonal design was adopted to optimize the preparation technology using the emulsion-solvent evaporation method of preparation technology.We prepared rifampicin poly（lactic-co-glycolic acid） copolymer microspheres and isoniazid poly（lactic-co-glycolic acid） copolymer microspheres.Biological binder was used to process these two kinds of microspheres into long-term slow-release two-component drug artificial bone.RESULTS AND CONCLUSION：According to the process optimization,two kinds of poly（lactic-co-glycolic acid） copolymer microspheres carrying 26% rifampicin or 28% isoniazid were prepared successfully,which were used to prepare artificial bone at a quality of 50%.The drug concentrations were kept at 0.02 and 0.03 mg/L after 90 days of in vitro release.These findings indicate that this kind of artificial bone is expected to provide a new and effective treatment for bone tuberculosis.
出处
《中国组织工程研究》
CAS
CSCD
2012年第38期7126-7130,共5页
Chinese Journal of Tissue Engineering Research
基金
天津市卫生局科技基金项目(2010KY10)~~
作者简介
鲍玉成，男，1975年生，天津市人，汉族，1999年天津市医科大学毕业，主要从事骨科（以骨结核为主的骨病）研究。
王勇，正高级工程师，天津市海河医院，天津市呼吸疾病研究所，天津市300350tjs．hhyywy@yahoo．com．cn
